Insmed, Inc. $INSM Shares Purchased by WCM Investment Management LLC

WCM Investment Management LLC boosted its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 51.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 15,707 shares of the biopharmaceutical company’s stock after purchasing an additional 5,339 shares during the period. WCM Investment Management LLC’s holdings in Insmed were worth $2,408,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its holdings in shares of Insmed by 0.5% in the first quarter. Dimensional Fund Advisors LP now owns 400,900 shares of the biopharmaceutical company’s stock valued at $65,474,000 after buying an additional 1,827 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Insmed by 13.1% during the first quarter. Parallel Advisors LLC now owns 2,291 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 266 shares during the last quarter. AlphaCentric Advisors LLC grew its holdings in shares of Insmed by 16.9% during the first quarter. AlphaCentric Advisors LLC now owns 8,874 shares of the biopharmaceutical company’s stock worth $1,451,000 after buying an additional 1,286 shares during the last quarter. KBC Group NV increased its position in Insmed by 9.8% in the 1st quarter. KBC Group NV now owns 37,347 shares of the biopharmaceutical company’s stock valued at $6,107,000 after acquiring an additional 3,334 shares during the period. Finally, SEB Asset Management AB acquired a new position in Insmed in the 1st quarter valued at about $27,075,000.

Insmed Trading Down 1.2%

NASDAQ INSM opened at $107.02 on Tuesday. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $23.20 billion, a P/E ratio of -18.61 and a beta of 0.78. Insmed, Inc. has a 52-week low of $90.39 and a 52-week high of $212.75. The firm has a 50-day moving average price of $105.79 and a 200 day moving average price of $135.16.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. During the same quarter in the previous year, the company earned ($1.42) EPS. The firm’s revenue for the quarter was up 229.7% compared to the same quarter last year. Equities research analysts expect that Insmed, Inc. will post -2.43 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on INSM. Bank of America upped their price objective on Insmed from $211.00 to $213.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Morgan Stanley raised Insmed from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $166.00 to $212.00 in a report on Monday, March 30th. Stifel Nicolaus boosted their target price on Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. JPMorgan Chase & Co. cut their price target on Insmed from $180.00 to $179.00 and set an “overweight” rating for the company in a research note on Monday, June 8th. Finally, Raymond James Financial began coverage on Insmed in a report on Friday, April 10th. They set an “outperform” rating and a $200.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Insmed has an average rating of “Moderate Buy” and an average target price of $209.13.

Insiders Place Their Bets

In related news, insider Michael Alexander Smith sold 1,806 shares of Insmed stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $95.82, for a total value of $173,050.92. Following the sale, the insider directly owned 37,648 shares in the company, valued at $3,607,431.36. The trade was a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Sara Bonstein sold 2,404 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $245,857.08. Following the transaction, the chief financial officer directly owned 69,082 shares in the company, valued at $7,065,016.14. This represents a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 54,590 shares of company stock valued at $5,793,738 over the last 90 days. 2.10% of the stock is owned by corporate insiders.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.